Targets › CEP290
3 programs from 3 companies in 4 trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Feb 2027.
Involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110. (UniProt, O15078)
Open in Phaseline: the race on CEP290, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ocugen | OCU400 Gene therapy vector for retinitis pigmentosa and Leber congenital amaurosis | RHO, NR2E3, CEP290 | Phase 3 | Retinitis Pigmentosa | Feb 2027 |
| Laboratoires Thea | Sepofarsen (QR-110) CEP290 mRNA positive modulator | CEP290 | Phase 3 | Leber Congenital Amaurosis 10 | Nov 2027 |
| ProQR Therapeutics | Sepofarsen (QR-110) CEP290 mRNA positive modulator | CEP290 | Phase 2 | Leber Congenital Amaurosis 10 | – |
Leber Congenital Amaurosis 10 (2) Retinitis Pigmentosa (2)
other (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.